false
0000315545
0000315545
2026-06-30
2026-06-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 30, 2026
PROVECTUS
BIOPHARMACEUTICALS, INC.
(Exact
name of registrant as specified in charter)
| Delaware |
|
001-36457 |
|
90-0031917 |
| (State
or other jurisdiction |
|
(Commission |
|
(IRS
Employer |
| of
incorporation) |
|
File
Number) |
|
Identification
No.) |
800
S. Gay Street, Suite 1610, Knoxville, TN 37929
(Address
of Principal Executive Offices) (Zip Code)
(866)
594-5999
(Registrant’s
Telephone Number, Including Area Code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
| None |
|
N/A |
|
N/A |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item
5.02. | Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers. |
On
May 14, 2026, the Board of Directors (the “Board”) of Provectus Biopharmaceuticals, Inc. (the “Company”) approved
the conversion of accrued but unpaid directors’ fees of current Board members owed through June 30, 2026 (“Accrued Fees”)
into the Company’s Series D-1 Preferred Stock (“Preferred Stock”) at a price per share equal to $2.862 and the issuance
of this Preferred Stock to current Board members. The Preferred Stock is being issued to satisfy payment of outstanding cash fees owed
to the Company’s directors and is not being issued as a separate award under the Company’s 2024 Equity Compensation Plan.
The total amount of Accrued Fees through June 30, 2026 will be $542,500.00, which would convert into 189,554 shares of Preferred Stock,
which would convert into 1,895,540 shares of Common Stock.
On
April 12, 2017, the Board approved the accrual of directors’ fees until such time as the Board authorized the payment of director
compensation, as reported on the Company’s Form 8-K filed on April 18, 2017.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
June 30, 2026
| |
PROVECTUS BIOPHARMACEUTICALS, INC. |
| |
|
|
| |
By: |
/s/ Heather Raines |
| |
|
Heather
Raines, CPA |
| |
|
Chief
Financial Officer |